Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, Eguchi Nakajima T, Baba E, Tsuda M, Moriwaki T, Esaki T, Tsuji Y, Muro K, Taira K, Denda T, Funai S, Shinozaki K, Yamashita H, Sugimoto N, Okuno T, Nishina T, Umeki M, Kurimoto T, Takayama T, Tsuji A, Yoshida M, Hosokawa A, Shibata Y, Suyama K, Okabe M, Suzuki K, Seki N, Kawakami K, Sato M, Fujikawa K, Hirashima T, Shimura T, Taku K, Otsuji T, Tamura F, Shinozaki E, Nakashima K, Hara H, Tsushima T, Ando M, Morita S, Boku N, Hyodo I. Yamazaki K, et al. Among authors: shinozaki k, shinozaki e. Ann Oncol. 2016 Aug;27(8):1539-46. doi: 10.1093/annonc/mdw206. Epub 2016 May 13. Ann Oncol. 2016. PMID: 27177863 Free article. Clinical Trial.
An internally and externally validated nomogram for predicting the risk of irinotecan-induced severe neutropenia in advanced colorectal cancer patients.
Ichikawa W, Uehara K, Minamimura K, Tanaka C, Takii Y, Miyauchi H, Sadahiro S, Fujita K, Moriwaki T, Nakamura M, Takahashi T, Tsuji A, Shinozaki K, Morita S, Ando Y, Okutani Y, Sugihara M, Sugiyama T, Ohashi Y, Sakata Y. Ichikawa W, et al. Among authors: shinozaki k. Br J Cancer. 2015 May 12;112(10):1709-16. doi: 10.1038/bjc.2015.122. Epub 2015 Apr 16. Br J Cancer. 2015. PMID: 25880011 Free PMC article.
Initial safety report on the tolerability of modified FOLFOX6 as adjuvant therapy in patients with curatively resected stage II or III colon cancer (JFMC41-1001-C2: JOIN trial).
Kotaka M, Yoshino T, Oba K, Shinozaki K, Touyama T, Manaka D, Matsui T, Ishigure K, Hasegawa J, Inoue K, Goto K, Sakamoto J, Saji S, Ohtsu A, Watanabe T. Kotaka M, et al. Among authors: shinozaki k. Cancer Chemother Pharmacol. 2015 Jul;76(1):75-84. doi: 10.1007/s00280-015-2757-0. Epub 2015 May 16. Cancer Chemother Pharmacol. 2015. PMID: 25983021 Free PMC article. Clinical Trial.
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I, Nam BH, Esaki T, Yoo C, Ryoo BY, Song EK, Cho SH, Kang WK, Yang SH, Zang DY, Shin DB, Park SR, Shinozaki K, Takano T, Kang YK; SOS study investigators. Ryu MH, et al. Among authors: shinozaki k. Ann Oncol. 2015 Oct;26(10):2097-101. doi: 10.1093/annonc/mdv316. Epub 2015 Jul 27. Ann Oncol. 2015. PMID: 26216386 Free article. Clinical Trial.
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial).
Kanai M, Kawaguchi T, Kotaka M, Shinozaki K, Touyama T, Manaka D, Ishigure K, Hasegawa J, Munemoto Y, Matsui T, Takagane A, Ishikawa H, Matsumoto S, Sakamoto J, Saji S, Yoshino T, Ohtsu A, Watanabe T, Matsuda F. Kanai M, et al. Among authors: shinozaki k. Ann Oncol. 2016 Jun;27(6):1143-1148. doi: 10.1093/annonc/mdw074. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27069012 Free article.
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T, Mishima H, Sawaki A, Shimokawa M, Inukai M, Shinozaki K, Tanioka H, Nasu J, Nishina T, Hazama S, Okajima M, Yamaguchi Y. Nagasaka T, et al. Among authors: shinozaki k. BMJ Open. 2016 Jun 2;6(6):e011454. doi: 10.1136/bmjopen-2016-011454. BMJ Open. 2016. PMID: 27256093 Free PMC article. Clinical Trial.
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G).
Miura Y, Sukawa Y, Hironaka S, Mori M, Nishikawa K, Tokunaga S, Okuda H, Sakamoto T, Taku K, Nishikawa K, Moriwaki T, Negoro Y, Kimura Y, Uchino K, Shinozaki K, Shinozaki H, Musha N, Yoshiyama H, Tsuda T, Miyata Y, Sugimoto N, Shirakawa T, Ito M, Yonesaka K, Yoshimura K, Boku N, Nosho K, Takano T, Hyodo I. Miura Y, et al. Among authors: shinozaki h, shinozaki k. Gastric Cancer. 2018 Jan;21(1):84-95. doi: 10.1007/s10120-017-0725-6. Epub 2017 May 11. Gastric Cancer. 2018. PMID: 28497176 Clinical Trial.
1,187 results